去甲基化药物联合CAG方案治疗老年急性髓系白血病的效果

Abstract
Figure/Table
References (15)
Related Citation (1)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of demethylation agents combined with CAG regimen in the treatment of acute myeloid leukemia in the elderly.Methods A total of 62 cases of elderly patients admitted for acute myeloid leukemia in our hospital from June 2013 to June 2018 were retrospectively analyzed, according to the different treatment methods, they were divided into the control group (34 cases) and the observation group (28 cases).The patients in the control group were treated with CAG regimen, while those in the observation group were treated with demethylation drugs plus CAG regimen (Aclacinomycin+Cytarabine+Granulocyte Colony Stimulating Factor).The clinical efficacy and adverse reactions of the two groups were compared.Results The total effective rate of the observation group was 75.00%, which was significantly higher than 55.88% of the control group, the difference was statistically significant (P＜0.05).There was no significant difference in the incidence of pulmonary infection, heart failure, nausea and vomiting,liver function damage, thrombocytopenia and granulocytopenia between the two groups (P＞0.05).Conclusion The clinical effect of demethylation drug plus CAG regimen in the treatment of elderly patients with acute myeloid leukemia is good, and it is safe and reliable.It does not increase the probability of complications.It is worthy of clinical promotion and application.

Key words： Acute myeloid leukemia in the elderly Demethylation agents CAG regimen

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Wei-hua
	GUO Zi-wen
	HE Hui-qing
	NIU Xiao-min
	LI Wei-chao

Cite this article:

LI Wei-hua,GUO Zi-wen,HE Hui-qing, et al. Effect of demethylated drugs combined with CAG regimen in the treatment of acute myeloid leukemia in the elderly[J]. 中国当代医药, 2019, 26(12): 61-63.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I12/61

[1]	张红霞，吴广胜，王燕.地西他滨联合半量CAG 方案治疗老年急性髓系白血病的临床疗效[J].中国老年学，2016，36（20）：5058-5060.
[2]	邵明，吕先萍，杨乾坤，等.DNA 甲基化对白血病ABO 基因表达的影响[J].中华血液学杂志，2016，37（9）：795-799.
[3]	Cortes J，Feldman E，Yee K，et al.Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia （OPAL）：a randomised open-label phase 2 study[J].Lancet Oncol，2013，14（4）：354-362.
[4]	张之南，沈悌.血液病诊断及疗效标准[M].3 版.北京：科学出版社，2007：106-134.
[5]	赵慧慧，钱思轩.老年人急性髓系白血病治疗进展：第57 届美国血液学会年会报道[J].白血病·淋巴瘤，2016，25（2）：79-82.
[6]	王瑞芳，茹丽娟，高素君.阿扎胞苷治疗老年人急性髓系白血病的研究进展[J].白血病·淋巴瘤，2016，25（5）：312-314.
[7]	把环环，刘心.急性髓细胞白血病的表观遗传学异常改变及其靶向治疗的研究进展[J].国际输血及血液学杂志，2016，39（5）：414-418.
[8]	王利军，于力.组蛋白去乙酰化酶抑制剂与AML1-ETO阳性急性髓细胞白血病的研究进展[J].国际输血及血液学杂志，2016，39（3）：238-242.
[9]	罗自勉，娄典，周新伏，等.非髓性白血病的其他恶性血液病中DNMT3A 基因突变的检测及临床意义[J].现代肿瘤医学，2017，25（19）：3131-3134.
[10]	唐旭东，张路，杨秀鹏，等.骨髓增生异常综合征患者低甲基化治疗失败后的治疗选择[J].白血病·淋巴瘤，2017，26（10）：577-581.
[11]	张睿.地西他滨联合CAG 方案治疗老年急性髓系白血病的效果观察[J].中国疗养医学，2018，27（3）：1.
[12]	白雪，肖霞，赵明峰，等.CAG 及CAG 联合地西他滨化疗方案治疗老年急性髓系白血病的疗效比较[J].临床荟萃，2018，33（3）：240-243.
[13]	杨融辉，沈静，张萌，等.初次诱导失败急性髓性白血病患者不同序贯诱导方案治疗的疗效观察[J].中国医科大学学报，2018，47（6）：494-498.
[14]	陆佳，姚福生，徐海涛.超小剂量地西他滨治疗骨髓增生异常综合征和急性髓系白血病11 例疗效观察[J].安徽医药，2018，22（5）：986-988.
[15]	刘现民.地西他滨联合CAG 方案治疗老年急性髓系白血病患者的效果与安全性分析[J].河南医学研究，2015，24（12）：97-98.